Filing Analysis
Allurion Technologies, Inc. announced the resignations of two board members and a subsequent decision to reduce the Board of Directors from five members to three members.
🚩 Red Flags
- Rapid departure of two board members within a three-day window.
- Significant reduction in Board size (from 5 to 3), which can impact oversight and governance stability.
- Resignation of a member from the Audit Committee, which is a critical governance function.
📋 Key Facts
- Krishna Gupta (Class I member) resigned from the Board and the Nominating and Corporate Governance Committee, effective August 17, 2026.
- Michael Davin (Class III member) resigned from the Board, Chairman of the Compensation Committee, and the Audit Committee, effective August 19, 2026.
- The Board voted to reduce its total size from five members to three members.
Allurion Technologies entered into an exchange agreement with affiliates of RTW Investments, LP to swap 392,766 shares of common stock for pre-funded warrants at a nominal exercise price. This follows the termination of a previous debt-for-equity conversion agreement that failed to close by February 2026.
🚩 Red Flags
- Related-party transaction: The exchange is with affiliates of RTW Investments, LP, which holds significant debt (RIFAs and 6% Convertible Secured Notes) and substantial equity.
- Debt remains outstanding: A previous attempt to convert debt into Series B Preferred Stock was terminated on July 21, 2026, leaving the original indebtedness intact.
- Bankruptcy trigger: The warrants contain explicit termination clauses triggered by a Chapter 7 or Chapter 11 filing, indicating high credit risk/distress context.
- Potential dilution: Pre-funded warrants at a nominal price ($0.0001) represent significant potential dilution for existing shareholders.
📋 Key Facts
- Exchange Agreement dated July 21, 2026, with RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., RTW Biotech Opportunities Operating Ltd., and 4010 Royalty Investments ICAV.
- 392,766 shares of Common Stock exchanged for an equal number of pre-funded warrants.
- Warrants have an exercise price of $0.0001 per share.
- Beneficial ownership limitation: initially 9.99%, adjustable up to 19.99% with 61 days' notice.
- Warrants automatically terminate upon foreclosure by RIFAs or the Company's filing for Chapter 7 or Chapter 11 bankruptcy.
- RTW affiliates previously held approximately 38% of outstanding Common Stock.
Allurion Technologies, Inc. announced the immediate resignation of its CEO and Board member, Shantanu K. Gaur, M.D., effective July 17, 2026. The company has not appointed a successor and will rely on COO Ojas Buch to oversee day-to-day operations.
🚩 Red Flags
- Immediate departure of a Chief Executive Officer without a pre-announced succession plan.
- Leadership vacuum: The Board has failed to appoint an interim or permanent CEO, leaving the company in a transitional state.
- Potential operational risk due to sudden shift in management responsibilities to the COO.
📋 Key Facts
- Shantanu K. Gaur, M.D. resigned as CEO and Board member effective July 17, 2026.
- The resignation was stated not to be the result of any disagreement with the Company or its Board regarding operations, policies, or practices.
- No interim or permanent CEO has been appointed as of the filing date.
- COO Ojas Buch will oversee day-to-day operations and certain responsibilities previously held by the CEO.
- The COO's title and compensation remain unchanged despite increased responsibilities.
Allurion Technologies, Inc. announced the resignation of Douglas Hudson from his position as a Class II member of the Board of Directors and his role on the Nominating and Corporate Governance Committee, effective June 30, 2026.
📋 Key Facts
- Douglas Hudson resigned from the Board of Directors and the Nominating and Corporate Governance Committee on June 30, 2026.
- The resignation was not due to any disagreement with management or the Board regarding operations, policies, or practices.
- The Board is currently evaluating a replacement for Mr. Hudson's committee position.
Allurion Technologies, Inc. announced the resignation of R. Jason Richey from the Board of Directors and his role as Chairperson of the Audit Committee, effective June 24, 2026.
🚩 Red Flags
- Loss of Audit Committee leadership (Chairperson) can create temporary governance gaps in financial oversight.
📋 Key Facts
- R. Jason Richey resigned from the Board of Directors on June 24, 2026.
- Mr. Richey also stepped down as the chairperson of the Audit Committee.
- The company stated the resignation was not due to any disagreement with management or the Board regarding operations, policies, or practices.
- The Board is currently evaluating a replacement for the Audit Committee chairperson position.
Allurion Technologies, Inc. has implemented a 1-for-15 reverse stock split of its common stock, effective June 18, 2026. The company will trade under the temporary symbol 'ALURD' for 20 business days before reverting to 'ALUR'.
🚩 Red Flags
- Reverse stock splits are typically used to artificially inflate share price to meet minimum listing requirements.
- The 'Cautionary Note' explicitly mentions noncompliance with New York Stock Exchange (NYSE) continued listing standards.
- The company is currently trading on the OTCQB Market, suggesting a prior delisting from a major exchange.
📋 Key Facts
- Reverse stock split ratio is 1-for-15.
- Effective date on the OTCQB Market is June 18, 2026.
- Temporary trading symbol 'ALURD' will be used for 20 business days.
- New CUSIP number is 02008G 300.
- Fractional shares will be rounded up to the next whole share.
- Public warrants (ALUR WS) adjusted: each warrant is now exercisable for 0.00378787 shares at an exercise price of $3,037.50 per share.
Allurion Technologies, Inc. (ALUR) has dismissed Deloitte & Touche LLP as its independent registered public accounting firm and appointed CBIZ CPAs P.C. as its replacement, effective May 20, 2026.
🚩 Red Flags
- Dismissal of a Big Four accounting firm (Deloitte) in favor of a smaller firm (CBIZ).
- Explicit acknowledgement of material weaknesses in internal control over financial reporting (ICFR) spanning multiple years (2024, 2025, and 2026).
- The timing of the auditor change coincides with ongoing internal control failures.
📋 Key Facts
- Deloitte & Touche LLP was dismissed as the auditor on May 22, 2026.
- CBIZ CPAs P.C. was appointed as the new auditor effective May 20, 2026.
- The company acknowledges material weaknesses in internal control over financial reporting for fiscal years 2024, 2025, and the interim period ending May 22, 2026.
- Material weaknesses include insufficient segregation of duties, lack of staff with public company accounting experience, and insufficient information systems controls.
Allurion Technologies was notified by the NYSE on March 6, 2026, that the exchange will commence delisting proceedings and has suspended trading of its common stock and warrants. The delisting is due to the company's failure to maintain an average global market capitalization of at least $15 million over a 30-day period.
🚩 Red Flags
- Market capitalization has fallen below the $15 million threshold, indicating extreme financial distress.
- Immediate suspension of trading on the NYSE.
- Transition to OTCID Market typically results in significantly lower liquidity and higher volatility.
- Warrants are extremely out-of-the-money with an exercise price of $202.50.
📋 Key Facts
- NYSE notified the company of delisting proceedings on March 6, 2026, due to non-compliance with Rule 802.01B.
- Average global market capitalization fell below $15 million over a 30 consecutive trading day period.
- Trading in Common Stock (ALUR) and Warrants (ALUR.WS) was suspended after market close on March 6, 2026.
- The company's securities are currently trading on the OTCID Market while an appeal is pending.
- Warrants have an exercise price of $202.50 per share of Common Stock.
- The company recently received FDA approval for the Allurion Gastric Balloon System.
Allurion Technologies received a formal delisting notice from the NYSE on March 2, 2026, after failing to meet the minimum $50 million stockholders' equity or market capitalization requirements. The NYSE will commence delisting proceedings, although the company intends to appeal the determination to maintain its listing status temporarily.
🚩 Red Flags
- Commencement of formal delisting proceedings by the NYSE.
- Prolonged non-compliance with listing standards dating back to August 2024.
- Market capitalization and stockholders' equity have fallen below the $50 million threshold.
- Heavy reliance on debt-to-equity restructuring and capital raising to attempt compliance.
📋 Key Facts
- Delisting notice received from NYSE on March 2, 2026, regarding Section 802.01B compliance.
- Company failed to maintain at least $50 million in stockholders' equity or a 30-trading day average market capitalization of $50 million.
- The company was previously notified of non-compliance on August 29, 2024.
- Allurion intends to appeal the NYSE's determination and request a review by a Committee of the Board of Directors of the Exchange.
- The company recently completed a warrant inducement transaction on February 24, 2026, and is negotiating a debt-for-preferred-stock exchange with its largest creditor.
Allurion Technologies entered into a warrant exercise inducement agreement to raise approximately $3.0 million in gross proceeds by significantly lowering the exercise price of existing warrants. In exchange for exercising 2.66 million warrants at the reduced price of $1.15, the company issued 5.32 million new warrants to the participating holders.
🚩 Red Flags
- Significant downward repricing of existing warrants (from $6.00/$5.23 to $1.15) indicates a lack of leverage and potential distress.
- Highly dilutive structure involving the issuance of two new warrants for every one warrant exercised.
- The relatively small capital raise ($3.0 million) suggests an urgent need for liquidity.
- Multiple 8-K items triggered (1.01, 3.02, 3.03) reflecting material modifications to security holder rights.
📋 Key Facts
- Existing warrants from January, February, and November 2025 had exercise prices reduced from as high as $6.00 to $1.15 per share.
- Exercising holders agreed to purchase 2,659,565 shares of common stock for cash.
- The company issued 5,319,130 new warrants (a 2-for-1 ratio relative to exercised warrants) with an exercise price of $1.15 and a five-year term.
- Total gross proceeds from the transaction are approximately $3.0 million.
- Roth Capital Partners acted as financial advisor, receiving a 5.0% fee on gross proceeds.
Allurion Technologies (ALUR) filed an 8-K under Item 7.01 (Regulation FD) on February 23, 2026, announcing that the FDA granted Pre-Market Approval (PMA) for its Allurion Gastric Balloon System featuring the Allurion Smart Capsule, targeting adults with obesity (BMI 30–40 kg/m²) aged 22–65 who have failed at least one prior weight loss program. While this represents a significant positive regulatory milestone for the company, the filing simultaneously contains explicit going concern language and references to the company's need for additional financing to support commercialization.
🚩 Red Flags
- Explicit going concern language in forward-looking statements: 'the ability of the Company to obtain sufficient financing to continue as a going concern'
- Capital raising uncertainty acknowledged: risk that capital raising process 'will not result in the Company pursuing any transactions or that any transaction, if pursued, will be completed on attractive terms or at all'
- PMA approval does not guarantee successful commercialization — company explicitly flags risk of inability to 'maintain FDA approval' and 'commercialize the Allurion Smart Capsule'
- Warrant exercise price of $202.50 per share vs. micro-cap profile suggests significant prior stock price deterioration and potential dilution overhang
- 10-K was amended in August 2025, potentially indicating post-filing corrections or material updates
📋 Key Facts
- FDA granted PMA (Pre-Market Approval) for the Allurion Gastric Balloon System featuring the Allurion Smart Capsule on February 23, 2026
- Indicated for adults with obesity aged 22–65 with BMI ≥ 30 kg/m² and ≤ 40 kg/m² who have had at least one unsuccessful weight loss attempt
- Filing made under Item 7.01 (Regulation FD); press release attached as Exhibit 99.1
- Forward-looking statements reference the company's ability to 'obtain sufficient financing to continue as a going concern'
- Company acknowledges risk that 'capital raising process will not result in the Company pursuing any transactions or that any transaction, if pursued, will be completed on attractive terms or at all'
- Company is classified as an Emerging Growth Company (EGC)
- Common stock (ALUR) and warrants (ALUR WS) listed on the New York Stock Exchange
- Warrant terms reference exercise price of $202.50 per share for 0.056818 shares of common stock
- Filing signed by Brendan M. Gibbons, Chief Legal and People Officer
- Most recent 10-K filed March 27, 2025 (amended August 19, 2025); most recent 10-Q filed November 17, 2025
Allurion Technologies, Inc. issued an 8-K to announce preliminary financial results for the quarter and fiscal year ended December 31, 2025.
📋 Key Facts
- Report date: January 12, 2026
- The company released selected preliminary financial results for the period ending Dec 31, 2025.
- The filing includes an exhibit (99.1) containing the full text of the press release regarding these results.
Allurion Technologies, Inc. held its 2025 Annual Meeting of Stockholders where shareholders approved a significant reverse stock split with a ratio between 1-for-1.5 and 1-for-20. The meeting also resulted in the re-election of directors, ratification of Deloitte & Touche LLP as auditors, and approval of several equity restructuring measures.
🚩 Red Flags
- Reverse stock split approval (ratio up to 1-for-20) often indicates a move to maintain minimum bid price requirements or combat delisting threats.
- Approval of option repricing, which can be viewed as dilutive and potentially unfavorable to existing common shareholders.
📋 Key Facts
- Shareholders approved a reverse stock split with a ratio between 1-for-1.5 and 1-for-20, to be determined by the Board.
- The Annual Meeting held on December 18, 2025, resulted in the re-election of Omar Ishrak, M.D., Douglas Hudson, and R. Jason Richey to the Board.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for FY2025.
- Stockholders approved an amendment to the 2023 Stock Option and Incentive Plan to increase authorized shares and amend 'Fully-Diluted Shares Outstanding'.
- Shareholders approved the repricing of certain outstanding stock options under the 2023 Plan.
- Approval was granted for share issuances related to Series B Preferred Stock conversion and private placement warrants to comply with NYSE Listing Rules.
Allurion Technologies announced two major financing events: a $5 million private placement of common stock and warrants, and an exchange agreement with RTW Investments to convert existing debt and revenue interest obligations into Series B convertible preferred stock.
🚩 Red Flags
- Significant dilution: Issuance of nearly 3 million new shares and warrants at $1.67 (below current implied value if conversion is $3.37).
- Debt-for-equity swap: Converting existing debt/revenue interest into preferred stock often indicates liquidity pressure.
- Dividend obligation: The Series B Preferred Stock carries a high 8.25% dividend that may be paid via increasing the accrued value, effectively adding to the company's long-term liabilities.
- Restrictive covenants: Includes a 'Specified Breach Event' related to maintaining a $3.0 million minimum unrestricted cash balance.
📋 Key Facts
- Entered into a Securities Purchase Agreement on Nov 11, 2025, for $5 million via issuance of 2,994,012 shares and warrants at $1.67 per share/warrant.
- Roth Capital Partners, LLC acting as exclusive placement agent with a 7% cash fee plus $100,000 in expenses.
- Entered into an Exchange Agreement with RTW Investments to exchange convertible senior secured notes and two Revenue Interest Financing Agreements (RIFAs) for Series B Preferred Stock.
- Series B Preferred Stock carries an 8.25% annual dividend rate, payable in cash or via increased accrued value if cash is unavailable.
- The conversion price for Series B Preferred Stock into Common Stock is $3.37 per share.
- Both transactions are subject to stockholder approval by January 31, 2026.
Milena Alberti-Perez resigned from the Board of Directors and her role as Audit Committee Chairperson effective September 30, 2025. The company stated the resignation was not due to any disagreement with management or operations.
🚩 Red Flags
- Vacating the Audit Committee Chairperson role can create temporary governance gaps, though no immediate successor was named in the filing.
📋 Key Facts
- Resignation date: September 30, 2025
- Departing Director: Milena Alberti-Perez (Class III member)
- Role vacated: Chairperson of the Audit Committee
- Reason provided: To focus on the media sector and a new board position at another public company
- Board size reduction: Decreased from nine to eight members as part of an efficiency/cost-reduction initiative
- The Board is currently evaluating a replacement for the Audit Committee Chair.
Allurion Technologies, Inc. has announced that its previously issued financial statements for the fiscal year 2024 and several quarters in 2024 and early 2025 should no longer be relied upon due to accounting errors regarding the fair value of a Revenue Interest Financing Agreement (RIFA) and convertible senior secured notes.
🚩 Red Flags
- Restatement of multiple years/quarters of financial data (Item 4.02).
- Existing material weaknesses in internal control over financial reporting already acknowledged.
- Potential for delisting by the NYSE if filings are not brought current timely.
- Risk of stockholder lawsuits or regulatory investigations mentioned in forward-looking statements.
📋 Key Facts
- The Audit Committee concluded that financial statements for the year ended Dec 31, 2024, and quarters ending March 31, 2025, Sept 30, 2024, June 30, 2024, and March 31, 2024, must be restated.
- Errors relate to the fair value accounting of a Revenue Interest Financing Agreement (RIFA) dated Feb 9, 2023, and $48.0 million in convertible senior secured notes issued in April 2024.
- The misstatements are non-cash and affect Other Comprehensive Income (Loss), Other Income (Expense), and Net Income (Loss).
- Management states the errors will not impact reported revenue, gross margin, operating expenses, or cash.
- The company has previously disclosed material weaknesses in internal control over financial reporting.
Allurion Technologies, Inc. announced that it is evaluating a potential miscalculation of non-cash items related to the fair value of its Revenue Interest Financing Agreement (RIFA) and convertible notes. The company believes these errors will likely result in a restatement of prior period financial statements.
🚩 Red Flags
- Likely restatement of prior period financial statements identified.
- Complexity in valuing derivative/financing instruments (RIFA and convertible notes) suggests potential accounting control weaknesses or valuation complexities.
📋 Key Facts
- The error relates to Other Comprehensive Income (Loss) and Other Income (Expense), which are non-cash items.
- The miscalculation is linked to the fair value of the Revenue Interest Financing Agreement (RIFA) and convertible notes.
- Management expects the restatement will NOT impact revenue, gross margin, operating expenses, or cash flow.
- The company issued a press release regarding financial results for the three and six months ended June 30, 2025.
Allurion Technologies is undergoing a massive strategic restructuring involving a 65% workforce reduction and a pivot toward GLP-1 combination therapy. The company also announced preliminary Q2 2025 financial results and expects to incur $1.5 million in severance charges.
🚩 Red Flags
- Massive workforce reduction (65% of staff) indicates severe distress or a radical change in business model.
- Significant restructuring charges ($1.5M) impacting the balance sheet/income statement.
- Preliminary financial results released without finalized audit, suggesting potential volatility or upcoming adjustments.
📋 Key Facts
- Board adopted a strategic restructuring plan on July 23, 2025.
- Reduction in force (RIF) involves approximately 70 employees, representing ~65% of the total workforce.
- Restructuring expected to be substantially complete by the end of Q3 2025.
- Estimated severance and related charges are approximately $1.5 million.
- Strategic pivot focuses on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry.
- Preliminary unaudited Q2 2025 financial results were announced on August 5, 2025.
Allurion Technologies, Inc. filed an 8-K to announce its financial results for the three months ended March 31, 2025. The filing includes a press release as Exhibit 99.1 but does not contain material changes to corporate structure or financing in the text provided.
📋 Key Facts
- Reporting period: Three months ended March 31, 2025.
- Filing date: May 14, 2025.
- The company is an emerging growth company.
- Financial results were released via press release (Exhibit 99.1).
Allurion Technologies, Inc. has entered into a Second Amendment to its Note Purchase Agreement, triggering mandatory conversion of $5 million in senior secured notes into common stock due to the company's market capitalization falling below $15 million. This event indicates severe liquidity distress and imminent delisting risks.
🚩 Red Flags
- Market capitalization has fallen below the critical $15 million threshold, triggering mandatory debt-to-equity conversion.
- The company explicitly acknowledges that market capitalization is 'reasonably expected' to remain below $15 million, which typically leads to NYSE delisting.
- Significant dilution risk: The mandatory and optional conversion provisions allow for massive issuance of new common stock at a floor price of $3.35.
- Death spiral-like mechanics: Conversion rates based on 5-Day VWAP (the lesser of the VWAP or the floor) are characteristic of highly dilutive financing.
📋 Key Facts
- Market Capitalization Condition triggered: Company's market cap is reasonably expected to remain below $15 million, a threshold for mandatory conversion.
- Mandatory Conversion: $5 million of principal amount of Notes will convert into 1,492,537 shares at a floor price of $3.35 per share.
- Additional Conversion Rights: Purchasers can convert up to an additional $5 million at the Floor Conversion Rate or via a 5-Day VWAP rate (subject to company discretion).
- Monthly Conversion Option: Purchasers may convert up to $1 million of principal per month for one year, totaling up to $12 million.
- Voting Agreement: Purchasers have agreed to abstain from voting or vote in proportion to other shareholders on certain matters until a termination date is reached.
Allurion Technologies, Inc. held a Special Meeting of Stockholders on April 10, 2025, where shareholders approved several proposals involving the repricing and issuance of warrants and significant amendments to an existing Note Purchase Agreement. These amendments include provisions to reduce conversion prices for convertible senior secured notes under specific market capitalization or time-based conditions.
🚩 Red Flags
- Significant dilution risk due to multiple approved warrant exercises and lowered conversion prices.
- Downside protection for noteholders via 'Market Capitalization Condition' ($15M threshold) which triggers price reductions, likely diluting common shareholders further during a decline.
- Multiple consecutive rounds of financing/repricing (July 2024, Jan 2025, Feb 2025) suggest ongoing liquidity needs or capital structure distress.
📋 Key Facts
- Stockholders approved the repricing of July 2024 warrants (Proposal 1).
- Stockholders approved issuance of shares upon exercise of January 2025 warrants (Proposal 2) and February 2025 warrants (Proposal 3).
- Approved an amendment to reduce conversion price for up to $10M in Notes if market capitalization falls below $15 million (Proposal 4).
- Approved an amendment to reduce conversion price for up to $17M in Notes for a one-year period regardless of market cap (Proposal 5).
Allurion Technologies, Inc. has postponed its special meeting of stockholders from April 4, 2025, to April 10, 2025. The company stated the delay is intended to allow more time for proxy solicitation and stockholder participation.
🚩 Red Flags
- Postponement of a special meeting often suggests the company is struggling to reach a quorum or obtain necessary votes for a critical corporate action (e.g., merger, board changes, or restructuring).
📋 Key Facts
- Special Meeting originally scheduled for April 4, 2025, at 12:00 p.m. ET.
- New meeting date set for April 10, 2025, at 12:00 p.m. ET.
- The purpose of the postponement is to facilitate broader stockholder participation and additional proxy solicitation.
- Valid proxies submitted before the original date remain valid for the reconvened meeting unless revoked.
Allurion Technologies, Inc. filed an 8-K to announce its financial results for the three and twelve months ended December 31, 2024.
📋 Key Facts
- Report date: March 26, 2025
- Reporting period: Three and twelve months ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) containing the financial results.
- Company is an emerging growth company.
Allurion Technologies, Inc. completed two private placements on February 20, 2025, raising approximately $6.1 million through the sale of common stock and warrants at $5.23 per share. The offerings include significant warrant components that require stockholder approval for exercise.
🚩 Red Flags
- Significant dilution potential due to the issuance of 1,800,000 warrants in the public offering and over 500,000 in the Leavitt placement.
- Warrant price reduction: The company is seeking to reduce an existing warrant exercise price from $30.00 down to $6.00 for a specific investor (Leavitt), which is highly dilutive to existing shareholders.
- Requirement for stockholder approval for both new warrants and the reduction of old warrant strike prices, creating significant regulatory/governance uncertainty.
📋 Key Facts
- Total gross proceeds from both offerings: approximately $6.1 million ($4.7M from public offering, $1.4M from Leavitt Private Placement).
- Public Offering: 900,000 shares of common stock and 1,800,000 warrants at $5.23 per share.
- Leavitt Private Placement: 267,686 shares of common stock and 535,372 warrants at $5.23 per share.
- Warrants from the public offering require NYSE stockholder approval before they can be exercised; a special meeting is targeted for on or before March 28, 2025.
- The company agreed to seek stockholder approval to reduce the exercise price of existing July 2024 Public Warrants held by Leavitt from $30.00 to $6.00 per share.
Allurion Technologies, Inc. announced that the French regulatory authority (ANSM) has cleared the company to resume sales of the Allurion Balloon in France, effective immediately.
📋 Key Facts
- Regulatory clearance received from Agence Nationale de Sécurité du Médicament (ANSM).
- The clearance allows for the immediate resumption of sales of the Allurion Balloon in France.
- Filing date: February 13, 2025.
Allurion Technologies, Inc. completed a $7.5 million private placement of 1,240,000 common shares and an equal number of warrants at $6.00 per share. The offering includes significant warrant repricing for existing holders to reduce their exercise price from $30.00 to $6.00.
🚩 Red Flags
- Significant warrant repricing (from $30.00 down to $6.00) which is highly dilutive to existing shareholders.
- Issuance of warrants that require NYSE stockholder approval, indicating potential governance/compliance hurdles.
- Heavy dilution via the issuance of 1.24M new shares and 1.24M new warrants.
📋 Key Facts
- Gross proceeds: Approximately $7.5 million.
- Offering structure: 1,240,000 common shares and 1,240,000 warrants at $6.00 per share/warrant.
- Closing date: January 27, 2025.
- Placement Agent: Roth Capital Partners, LLC (7% cash fee + up to $100,000 expense reimbursement).
- Warrant Repricing: Existing July 2024 Public Warrants will be subject to stockholder approval to reduce exercise price from $30.00 to $6.00.
- Use of proceeds: Working capital and general corporate purposes.
Allurion Technologies, Inc. entered into a subscription agreement with RTW Investments, LP for a $2.5 million private placement of common stock. The transaction closed on January 16, 2025, and includes a commitment by the company to file a resale registration statement within 45 days.
🚩 Red Flags
- Private placement of equity often indicates a need for immediate liquidity/cash runway extension.
- Potential dilution for existing shareholders upon the filing and effectiveness of the resale registration statement.
📋 Key Facts
- Entered into subscription agreement with funds affiliated with RTW Investments, LP on January 14, 2025.
- Total aggregate purchase price of approximately $2.5 million.
- Issuance of 841,751 shares at a price of $2.97 per share.
- The company is required to file a resale registration statement with the SEC within 45 days after the closing date (January 16, 2025).
- Registration statement must be declared effective by the SEC within 90-120 days depending on review status.
Allurion Technologies, Inc. has entered into an Omnibus Amendment to its existing debt and revenue interest financing agreements with RTW Investments. The filing also confirms a 1-for-25 reverse stock split effective January 3, 2025.
🚩 Red Flags
- Reverse stock split (1-for-25) executed on Jan 3, 2025.
- Stringent financial and regulatory covenants in the Omnibus Amendment (cash minimums and revenue targets).
- Requirement to secure FDA Marketing Authorization by June 2026 as a condition of financing terms.
- Potential dilution via 5% equity issuance/Series A-1 preferred stock for lenders.
- Risk of non-compliance with NYSE listing standards mentioned in forward-looking statements.
📋 Key Facts
- Executed an 'Omnibus Amendment' on January 7, 2025, amending the Note Purchase Agreement and two Revenue Interest Financing Agreements (RIFAs).
- The amendment requires the company to maintain specific minimum unrestricted cash balances in U.S. controlled accounts.
- Company must meet minimum trailing twelve-month consolidated revenue targets, tested quarterly starting September 30, 2025.
- Regulatory milestones: Allurion France must regain marketing authorization in France by Dec 31, 2025; Allurion OpCo must receive FDA Marketing Authorization for the U.S. by June 30, 2026.
- Investors/Purchasers to receive a 5% equity stake (via common stock or Series A-1 preferred stock) in connection with a planned $12M+ capital raise due by Feb 15, 2025.
- Board of Directors expansion: Investors gain the right to designate a second director (initially Jason Richey).
- Completed a 1-for-25 reverse stock split effective January 3, 2025.
Allurion Technologies, Inc. announced the appointment of R. Jason Richey to its Board of Directors as a Class II director, effective December 30, 2024.
🚩 Red Flags
- The director was recommended by RTW Investments, LP, a significant stockholder (potential related-party influence).
📋 Key Facts
- R. Jason Richey appointed to the Board on December 30, 2024.
- The appointment fills a vacancy created by an increase in Board size from eight to nine members.
- Mr. Richey is currently an independent consultant to RTW Investments, LP, which is a stockholder of the Company.
- Mr. Richey's compensation will follow the Company’s existing non-employee director compensation policy.
- Professional background includes leadership roles at Cytrellis Biosystems, Cutera, Inc., and LivaNova, PLC.
Allurion Technologies, Inc. has announced a 1-for-25 reverse stock split to be effective as of January 3, 2025. The move follows stockholder approval at the company's 2024 Annual Meeting.
🚩 Red Flags
- Reverse stock split is a common defensive measure to avoid delisting due to low share price.
- Forward-looking statements explicitly mention risks regarding noncompliance with NYSE continued listing standards and the ability to meet such standards.
📋 Key Facts
- Reverse stock split ratio is set at 1-for-25.
- Effective date for the reverse split is January 3, 2025, at 12:01 a.m. ET.
- Trading on NYSE will commence on a split-adjusted basis on January 3, 2025.
- The company's ticker symbol 'ALUR' remains unchanged.
- Warrants (ALUR WS) will be adjusted; each whole public warrant will become exercisable for 0.056818 shares at an exercise price of $202.50 per share.
Allurion Technologies, Inc. held its reconvened Annual Meeting of Stockholders on December 16, 2024, where shareholders approved a significant reverse stock split and several other structural proposals.
🚩 Red Flags
- Approval of a reverse stock split (ratio 1:10 to 1:25) often indicates an attempt to boost share price to maintain exchange listing requirements.
- Shareholder approval required for multiple share issuances to comply with NYSE rules, suggesting potential dilution or regulatory pressure regarding ownership thresholds.
📋 Key Facts
- Shareholders approved an amendment to the Certificate of Incorporation to implement a reverse stock split with a ratio between 1-for-10 and 1-for-25.
- Stockholders approved the issuance of shares upon conversion of Notes to comply with NYSE Listing Rule 312.03(b)(i).
- Stockholders approved the issuance of shares upon conversion of Series A Preferred Stock and Private Placement Warrants to comply with NYSE Listing Rule 312.03(b)(i).
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year 2024.
- Three Class I directors (Shantanu Gaur, Krishna Gupta, and Nicholas Lewin) were re-elected to the Board.
Allurion Technologies, Inc. announced the resignation of its Chief Financial Officer, Christopher Geberth, effective November 13, 2024. The CEO, Shantanu Gaur, will assume the roles of principal financial and accounting officer during the transition.
🚩 Red Flags
- Sudden departure of the CFO in a micro-cap environment can signal internal instability or upcoming reporting challenges.
- CEO assuming PFO/PAO duties increases concentration of control and operational burden on executive management.
📋 Key Facts
- CFO Christopher Geberth is resigning to pursue other interests, effective close of business on Nov 13, 2024.
- Geberth will remain as a consultant to provide advisory services post-resignation.
- CEO Shantanu Gaur will serve as Principal Financial Officer (PFO) and Principal Accounting Officer (PAO) until a replacement is found.
- The company has engaged CFGI, LLC to assist with the financial leadership transition.
Allurion Technologies, Inc. filed an 8-K to announce its financial results for the three and nine months ended September 30, 2024.
📋 Key Facts
- Report date: November 13, 2024
- Reporting period: Three and nine months ended September 30, 2024
- The filing includes a press release as Exhibit 99.1 regarding financial results.
- Company is an emerging growth company.
Allurion Technologies, Inc. announced that its Additional RIFA Investors have fully exercised their option to convert up to $7.5 million of previously paid purchase price into new financing via a Revenue Interest Financing Agreement (New RIFA). This transaction effectively converts equity-based value into debt/revenue interest obligations for the company's subsidiary.
🚩 Red Flags
- Conversion of equity/purchase price into revenue interest obligations increases the company's non-dilutive but cash-flow sensitive liabilities.
📋 Key Facts
- Additional RIFA Investors exercised their 'Investment Conversion' in full on October 22, 2024.
- The conversion amount is $7,500,000.
- The New RIFA was entered into on October 30, 2024.
- Terms of the New RIFA are substantially identical to the Original RIFA dated February 9, 2023.
- The financing is provided to Allurion Opco (the company's wholly-owned subsidiary).
Allurion Technologies, Inc. announced the date for its first Annual Meeting of Stockholders, scheduled for December 11, 2024. The filing also outlines procedures and deadlines for stockholder proposals and director nominations.
📋 Key Facts
- Annual Meeting Date: Wednesday, December 11, 2024.
- Record Date for voting: November 6, 2024.
- Deadline for Rule 14a-8 shareholder proposals: November 7, 2024.
- Deadline for non-Rule 14a-8 nominations/proposals: November 7, 2024.
Allurion Technologies, Inc. received a notice from the NYSE stating it is non-compliant with the Minimum Market Capitalization Standard ($50M) and has previously failed to meet minimum average closing price requirements. The company intends to submit a plan to regain compliance within 45 days.
🚩 Red Flags
- Delisting notice for Minimum Market Capitalization Standard.
- Multiple delisting/non-compliance notices (Price requirement on Aug 12 and Market Cap requirement on Aug 29).
- Stockholders' equity is below the $50M threshold required by NYSE.
- Potential for reduced liquidity and market price volatility if delisting occurs.
📋 Key Facts
- Received NYSE notice on August 29, 2024, regarding failure to meet the Minimum Market Capitalization Standard (Section 802.01B).
- Average market capitalization was less than $50 million over the 30 trading-day period ending August 29, 2024.
- Stockholders' equity as of August 29, 2024, was also less than $50 million.
- The company previously received a notice on August 12, 2024, regarding non-compliance with the minimum average closing price requirement (Section 802.01A).
- Shares will trade under the symbol 'ALUR.BC' to indicate they are below listing criteria.
- The company has an 18-month cure period to regain compliance.
Allurion Technologies, Inc. announced the appointment of Keith Johns to its Board of Directors as a Class III director, effective September 2, 2024.
📋 Key Facts
- Keith Johns appointed to the Board of Directors on September 2, 2024.
- The appointment fills a vacancy created by an increase in Board size from seven to eight members.
- Compensation for Mr. Johns is expected to be consistent with existing non-employee director compensation policies.
- No specific arrangement or conflict of interest was disclosed regarding the appointment.
Allurion Technologies, Inc. received a notice from the NYSE stating it is non-compliant with minimum bid price requirements after its average closing price fell below $1.00 over the 30 trading days ending August 8, 2024. The company is considering all options to regain compliance, including a potential reverse stock split.
🚩 Red Flags
- Delisting notice from NYSE (non-compliance with minimum bid price requirement).
- Potential for a reverse stock split to artificially inflate share price.
- Risk of reduced liquidity and market volatility if delisting occurs.
📋 Key Facts
- Received NYSE notice on August 12, 2024, regarding non-compliance with Section 802.01C of the NYSE Listed Company Manual.
- The deficiency is due to an average closing price below $1.00 over the 30 trading-day period ending August 8, 2024.
- The company has a six-month cure period to regain compliance.
- Compliance can be achieved if the stock closes at or above $1.00 on the last trading day of any month during the cure period and maintains a 30-day average of $1.00.
- Management is considering a reverse stock split, subject to stockholder approval, as a method to regain compliance.
Allurion Technologies, Inc. filed an 8-K to announce its financial results for the three and six months ended June 30, 2024. The filing includes a press release detailing the company's recent operational and financial performance.
📋 Key Facts
- Reporting period: Three and six months ended June 30, 2024.
- Filing date: August 13, 2024.
- The filing includes a press release (Exhibit 99.1) regarding financial results.
The French regulatory authority (ANSM) has suspended sales of the Allurion Balloon in France, forcing the company to withdraw the device from that market pending a remediation plan. The company is contesting the decision but must address concerns regarding advertising, follow-up programs, and adverse event reporting.
🚩 Red Flags
- Regulatory suspension of a core product in a major market (France).
- Mandatory product withdrawal from a specific geographic region.
- Potential impact on revenue and market share if remediation is delayed or unsuccessful.
📋 Key Facts
- The Agence Nationale de Sécurité du Médicament (ANSM) suspended sales of the Allurion Balloon in France on August 6, 2024.
- Allurion Technologies is withdrawing the device from the French market pending a remediation plan.
- Regulatory concerns focus on advertising strategy, follow-up programs, and adverse event management.
- The company claims complication rates remain in line with published literature and are lower than other weight loss products.
Allurion Technologies, Inc. announced that its underwriters partially exercised their over-allotment option in connection with a recent public offering. This exercise resulted in the sale of an additional 1,927,265 shares of common stock, providing approximately $2.3 million in gross proceeds.
🚩 Red Flags
- Significant dilution potential due to the large number of warrants (over 16 million shares) issued in the broader offering context.
📋 Key Facts
- Underwriters partially exercised their over-allotment option on July 5, 2024.
- The exercise involved the purchase of 1,927,265 additional shares of Common Stock.
- Gross proceeds from this partial exercise are approximately $2.3 million.
- The offering price for the shares is $1.20 per share.
- The transaction was conducted pursuant to an Underwriting Agreement with Jefferies LLC and TD Securities (USA) LLC.
Allurion Technologies, Inc. announced a dual-track financing involving a public offering of common stock and warrants via Jefferies LLC and TD Securities, alongside a private placement of Series A non-voting convertible preferred stock to RTW Investments, LP.
🚩 Red Flags
- Related-party transaction: RTW Investments is a significant stockholder and received a private placement allocation.
- Potential dilution: Issuance of over 14 million new shares plus warrants represents substantial potential dilution for existing shareholders.
- Mandatory redemption clause: The company must redeem Series A Preferred Stock at market price if not converted by end of 2026, creating future cash outflow obligations.
📋 Key Facts
- Public Offering: 14,406,508 shares of Common Stock and Public Warrants at $1.20 per share; expected gross proceeds of ~$17.3M - $20M.
- Private Placement: Sale of 2,260,159 shares of Series A non-voting convertible preferred stock and Private Placement Warrants to RTW Investments for ~$2.7M.
- RTW Investments is a significant stockholder and a related party under NYSE rules.
- Series A Preferred Stock features mandatory redemption if not converted by December 31, 2026.
- The company must seek stockholder approval for the conversion of Series A Preferred Stock by December 31, 2025.
Allurion Technologies, Inc. furnished an investor presentation via its website on June 25, 2024. This filing is a routine disclosure under Item 7.01 to provide supplemental information to the market.
📋 Key Facts
- The company made an investor presentation available on its website on June 25, 2024.
- The presentation is furnished as Exhibit 99.1 and is not considered 'filed' for liability purposes under Section 18 of the Exchange Act.
- The filing includes interactive data files (XBRL) in the cover page.
Allurion Technologies, Inc. filed an 8-K to announce its financial results for the three months ended March 31, 2024. The filing primarily serves as a vehicle to incorporate the company's quarterly earnings press release by reference.
📋 Key Facts
- Reporting period: Three months ended March 31, 2024.
- Filing date: May 14, 2024.
- The filing includes a press release (Exhibit 99.1) containing financial results.
- Company is classified as an 'emerging growth company'.
Allurion Technologies, Inc. issued an 8-K to announce preliminary financial results for the quarter ended March 31, 2024.
📋 Key Facts
- The filing relates to the announcement of selected preliminary financial results for the fiscal quarter ended March 31, 2024.
- The company is an emerging growth company.
- The report was filed on April 30, 2024.
Allurion Technologies issued $48 million in convertible senior secured notes to RTW Investments, LP to refinance existing debt. The deal includes complex conversion terms, a significant increase in royalty rates on revenue, and strict financial maintenance covenants.
🚩 Red Flags
- Significant dilution risk due to convertible notes and potential price reset provisions.
- Increased cost of capital via the doubling of royalty rates (from 6% to 12%) on revenue interest financing.
- Strict financial maintenance covenants, including minimum cash requirements ($12.5M) and profitability requirements for non-US operations starting Dec 31, 2025.
- Complex conversion restrictions: the company cannot issue more than 1% of outstanding shares upon conversion until stockholder approval is obtained.
📋 Key Facts
- Issued $48 million aggregate principal amount of convertible senior secured notes to RTW Investments, LP (and affiliates).
- Notes bear 6.0% annual interest, payable quarterly in cash or in-kind for the first three years.
- Maturity date is April 16, 2031.
- Initial conversion price of ~$3.26 per share (a 35% premium to the April 12, 2024 VWAP).
- The deal includes a reset provision that could lower the conversion price in future equity financings.
- Revenue Interest Financing Agreement (RIFA) royalty rate increased from 6% to 12% for net sales under $100M through Dec 31, 2026.
- Requires maintenance of at least $12.5 million in unrestricted cash in U.S. controlled accounts.
Allurion Technologies, Inc. filed an 8-K to announce its financial results for the three and twelve months ended December 31, 2023. The filing primarily serves as a vehicle to furnish the earnings press release via Exhibit 99.1.
📋 Key Facts
- Report date: March 21, 2024
- Reporting period covered: Three and twelve months ended December 31, 2023
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an 'emerging growth company'
Allurion Technologies, Inc. appointed Milena Alberti-Perez to the Board of Directors and as Chair of the Audit Committee. This appointment was made to ensure compliance with NYSE listing requirements regarding audit committee independence.
🚩 Red Flags
- The filing implies a prior period of non-compliance with NYSE independence requirements for the Audit Committee.
📋 Key Facts
- Milena Alberti-Perez appointed as Class III director effective March 11, 2024.
- Appointed as Chair of the Audit Committee.
- Appointment restores compliance with NYSE listing requirement 303A.07 (Audit Committee independence).
- Board determined Ms. Alberti-Perez is 'independent' under NYSE and SEC rules.
- Compensation will follow the Company’s Non-Employee Director Compensation Policy.
Allurion Technologies, Inc. issued an 8-K to announce preliminary financial results for the quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- The filing is a release of selected preliminary financial results via press release (Exhibit 99.1).
- Reporting period: Quarter and Year ended December 31, 2023.
- Filing date: January 8, 2024.